CVS is opting against covering a twice-yearly injectable HIV prevention drug, drawing criticism from advocates who are ...

At the International AIDS Society meeting this year, a young woman from South Africa spoke. She is the first Black woman from ...

Gilead stock toppled Thursday on a report CVS won't add the company's new HIV prevention drug, Yeztugo, to its commercial ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

E xecutives at Gilead Sciences, the biotech behind a long list of HIV treatments and preventative medicines, have spoken with ...

Malawi is bolstering efforts to protect its phenomenal progress in the fight against HIV as sudden donor funding cuts, especially from the United States (US), threaten vital services. Like many ...

Gilead raised its 2025 earnings and sales outlook after posting better-than-expected Q2 results, led by strong HIV and oncology drug sales.

(Reuters) -Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year financial outlook, citing better-than-expected sales of HIV drugs.

With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to stop the spread of HIV before the system fails them.

How Deborah Wafer is closing the HIV gap for Black women. Her mission to bridge the shocking disconnect between risk and prevention access.

Gilead Sciences said a key European regulatory committee recommended accelerated approval of its twice-yearly lenacapavir injection for HIV prevention. Gilead on Friday said the recommendation by ...

Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention ...